Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti-di-diethylenetriaminepentaacetic acid F(ab')2 antibody

Cancer
Frits AartsDavid M Goldenberg

Abstract

Antibody-based imaging agents are available commercially, but their success has been limited, mainly because of low contrast and the emergence of 2-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) scanning. In pretargeting, administration of the radionuclide is separated from the antibody, thereby enhancing image contrast and allowing detection at earlier time points after injection. The authors conducted an open-label, single-arm trial that assessed a pretargeting procedure in which an anticarcinoembryonic antigen x (anti-CEA x) anti-diethylenetriaminepentaacetic acid (anti-DTPA)-indum (In) antibody was used in combination with a (111)In-labeled di-DTPA peptide for the diagnostic imaging of CEA-expressing colorectal cancer. Three patients received the (111)In peptide alone to investigate tumor targeting, organ distribution, and clearance of the peptide. Thereafter, 11 patients received the bispecific antibody (bsAb) (5 mg) to pretarget the tumor. After 3 to 5 days, patients were injected with 185 megabecquerels of (111)In-labeled peptide to assess the optimal interval for best image quality. Fourteen patients with primary colorectal cancer were enrolled. One of 3 patients who received (111)In peptide alone had l...Continue Reading

References

Oct 6, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert M SharkeyDavid M Goldenberg
Oct 6, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Adrienne H BrouwersWim J G Oyen
Mar 7, 2006·Seminars in Nuclear Medicine·Fabio P EstevesRaghuveer K Halkar
Mar 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-François ChatalUNKNOWN French Endocrine Tumor Group
Nov 16, 2006·European Journal of Nuclear Medicine and Molecular Imaging·Eric VisserFrans Corstens
Mar 4, 2008·Update on Cancer Therapeutics·David M GoldenbergRobert M Sharkey

❮ Previous
Next ❯

Citations

Oct 12, 2012·International Journal of Nanomedicine·Mariana Campos da PazZulmira G M Lacava
Jun 3, 2011·World Journal of Gastroenterology : WJG·Vera ArtikoVladimir Obradović
Nov 6, 2012·Advanced Drug Delivery Reviews·Yang ZhouMartin W Brechbiel
Apr 22, 2015·International Journal of Cancer. Journal International Du Cancer·Martin C BoonstraAlexander L Vahrmeijer
May 23, 2015·Nature Reviews. Cancer·Steven M LarsonOliver W Press
Sep 22, 2017·Journal of Hematology & Oncology·Shengnan YuKongming Wu
Oct 20, 2012·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Rafke SchoffelenOtto C Boerman
May 22, 2021·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Vilma I J Jallinoja, Jacob L Houghton

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.